Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Eye.eyechart.ocular

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).

The company intends to submit an NDA for Axpaxli following year one data, if positive, from its ongoing SOL-1 Phase 3 clinical trial, for which data are on track for the first quarter of 2026.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.